ZTS, Zoetis Inc.
We believe we are an industry leader in animal health R&D, with a track record of generating new products a nd product lifecycle innovation, which is defined as R&D programs that leverage existing animal health products by adding new species or claims, achieving approvals in new markets or…
Read top to bottom, the owner's questions in the order an owner asks them: what the business is, whether the record holds, whether it survives and is any good, and what you would be paying. New to the questions? Start with the Method.
The business in brief
read the 10-K →What this business is and what moves its needle, read from the numbers in its filings. The quantitative detail is in the sections below; the verdict is left to you.
- What it is
- A consumer-brand business, where the durable asset is the brand and its hold on the shelf.
- What moves the needle
- Volume against price, and shelf position. What decides it: whether it can raise prices without losing the customer, and whether the brand still commands its margin.
- Is it a good business?
- Return on capital has run in the teens (median 19%, above 15% in 10 of 10 years). Owner earnings agree: roughly 21% of revenue reaches owners as cash, consistently. Returns like these are solid but short of clear franchise economics; whether they hold is what the 10-K settles, not the multiple.
Every line here is arithmetic from the company's own filings, not a model's opinion, and each figure appears in full in the sections below.
Where the money comes from
read the 10-K →46% of revenue comes from outside the United States.
- United States54%$5.1B
- Other emerging markets10%$913M
- Other developed markets7%$641M
- Brazil4%$393M
- Australia3%$329M
- United Kingdom3%$325M
- Other17%$1.7B
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record, 2016–2025
realized figures from each filing, no estimates| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RevenueRevenue | $4.9B | $5.3B | $5.8B | $6.3B | $6.7B | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B | $9.5B |
| Gross marginGross mgn | 66% | 67% | 67% | 68% | 69% | 70% | 70% | 70% | 71% | 72% | 72% |
| Operating marginOp. mgn | 28.6% | 32.1% | 32.6% | 32.3% | 33.4% | 34.9% | 35.6% | 37.2% | 36.2% | 37.8% | 37.5% |
| Net incomeNet inc. | $821M | $864M | $1.4B | $1.5B | $1.6B | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B | $2.7B |
| EPS (diluted)EPS | $1.65 | $1.75 | $2.93 | $3.11 | $3.42 | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 | $6.33 |
| Owner earningsOwner earn. | $497M | $1.1B | $1.5B | $1.3B | $1.7B | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B | $2.2B |
| ROICROIC | 18% | 19% | 19% | 18% | 17% | 20% | 19% | 22% | 24% | 23% | 28% |
| Cash & investmentsCash+inv | $727M | $1.6B | $99M | $0 | — | — | — | — | — | — | $1.9B |
| Net debt / (cash)Net debt | $3.7B | $3.4B | $6.3B | $6.4B | $7.2B | $6.6B | $7.9B | $6.6B | $6.6B | $9.0B | $7.1B |
| Book value / shareBVPS | $2.98 | $3.59 | $4.49 | $5.62 | $7.88 | $9.53 | $9.36 | $10.81 | $10.49 | $7.51 | $7.65 |
Owner’s Scorecard
Will it survive?
- Can it pay its interest? 16.1×ComfortableOperating income $3.6B ÷ interest expense $222M
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- ModerateTotal debt $9.0B ÷ operating income $3.6B
Years of operating profit it would take to repay all debt. A first read, not a credit rating: it's gross debt (not netted against cash) over EBIT (not EBITDA), and a cyclical year distorts it.
- Debt, net of cash $7.5BMeaningful net debtCash $1.6B − debt $9.0B
Netting $1.6B of cash and short-term investments against $9.0B of debt leaves $7.5B owed, about 2.1× a year's operating profit, versus the gross figure above. Net debt is the leverage figure that matters; the gross ratio above ignores the cash already set against it. Strategic or illiquid investments aren't counted here.
- Capital-hungryDSO 61 + DIO 333 − DPO 67 days
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- ExceptionalNOPAT $2.8B ÷ invested capital $10.8B (debt + equity − cash)
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; below ~8% the company may destroy value as it grows. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Cash machineOwner Earnings $2.3B = operating cash $2.9B − capex $621M
What an owner could take out without starving the business. That's 24% of revenue. Treating stock comp as the real expense it is (less $83M of SBC) leaves $2.2B. Honest caveat: capex here blends maintenance and growth, so steady-state Owner Earnings may run higher (see capex vs. depreciation).
- Cash-backedCash from ops $2.9B ÷ net income $2.7B
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Returns most of itDividends + buybacks $3.2B ÷ Owner Earnings $2.3B
Of $2.3B Owner Earnings, $3.2B (142%) went back to shareholders, $0 dividends, $3.2B buybacks. Net of $83M stock comp, the real buyback was about $3.2B. Returning most of it signals a mature cash machine; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 1.28×ExpandingCapex $621M ÷ depreciation $487M
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Durability & moat, 2016–2025
A moat is a high return that doesn’t fade, reinvested at high returns. Here is what the record says, judgments, not another chart of the numbers.
- Profitable years 10 of 10
Never lost money over the record, the earnings stability Graham insisted on.
- Return on capital ≥ 15% 10 of 10 yrs
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 29% (FY2016) → 38% (FY2025)
Margins widened over the record, pricing power intact or improving.
- Reinvestment, incremental ROIC 28%
Every extra dollar the company reinvested earned a high return, it is still compounding, not coasting on an old moat.
- Owner earnings growth +12%/yr
Free cash to owners grew about 12% a year over the record.
- Worst year 2016 · 28.6% op. margin
Stayed profitable even in its hardest year, the resilience that survives recessions.
- Share count −1.3%/yr
The share count is shrinking, buybacks are quietly growing your slice of the business.
Solvent is not the same as cheap; growing is not the same as good. These are vital signs, not a verdict, the judgment is yours, and the filing is one click away.
How the cash was used, 2016–2025
Over the record, the business generated $20.1B of operating cash, and how management split it is, as Buffett insists, the job that matters most. Here it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$4.8B · 24%
- Buybacks$10.9B · 54%
- Retained (debt / cash)$4.4B · 22%
It reinvested $4.8B (24%) back into the business and returned $10.9B (54%) to owners, $0 in dividends, $10.9B in buybacks. Total debt rose $4.6B across the span.
Buybacks are gross of stock issued to employees; net of that, the real return to owners is lower (see Management & pay). And the mix alone doesn't grade management, what matters is the return earned on the dollars reinvested (see incremental ROIC in the durability report).
Management & pay
Two questions Buffett actually asks about pay: is stock compensation, a real expense, whatever the income statement pretends, quietly large, and is the top wildly out of line with the floor. He's no populist about it; he just wants pay that's rational and earned, and comp committees that aren't lapdogs.
- Stock-based compensation$83M
The slice of the business handed to employees in shares this year, 1% of revenue, equal to 2% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. And note the trap, the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Graham’s defensive-investor test
4 of 6 metGraham gave the defensive investor seven numerical criteria in The Intelligent Investor. Here they are, run mechanically on the filings, his framework, not our verdict. Meeting them is a floor of safety, not a reason to buy; missing one is no veto, since many fine modern businesses fail his strictest liquidity tests by design. The worth is in seeing exactly where a company stands against the canon, every number sourced.
- Adequate size PassRevenue ≥ $2B · $9.5B
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 3.03×
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $9.0B vs $4.5B WC
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability PassA profit every year (10-yr record) · no losses
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · none paid
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth PassEarnings +33% over the record · +141%
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Earnings are $6.02/share and book value $7.51/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Graham would be the first to say a checklist is a starting point, not an answer. These are his defensive, bargain-hunter's tests, the cigar-butt lens. Buffett and Munger grew past it, paying fair prices for wonderful businesses; that lens lives in the moat and owner-earnings work above, and both still matter. Clearing Graham’s tests earns a closer look; failing them earns harder questions, not a dismissal.
What the price implies
reverse-DCFA price is the one input we don't pull, you bring it. Type today's close (read it off any broker or quote site) and see the owner-earnings growth you'd have to believe to justify it, set beside what Zoetis Inc. has actually delivered. Nothing is stored; the number stays in your browser.
Enter a price above to run it.
Graham capped the multiple at 15×; Buffett and Munger let that rule go, a wonderful business can deserve 50× if the thesis holds. Read it as the bargain-hunter's floor, not a ceiling on good sense.
The discount rate is your interest rate, what a dollar years from now is worth today, anchored to the long-term Treasury yield (~4–5% today, plus whatever premium you want for risk). Drag it toward the risk-free rate and watch how much growth the price suddenly “needs”: interest rates are gravity on valuations.
Owner earnings $2.2B on 422M diluted shares; net debt $7.1B. This is a lens, not a price target, it says what you'd have to believe, not what the company is worth, and it runs on one year of (noisy) owner earnings at assumptions you can see and change.
What the filing emphasizes, FY2025
read the 10-K →Each year a 10-K must name what could go wrong, in the company's own words. Here are the ones Graham and Buffett would stop on, each set against the figure from the same filings that bears on it, anchored to a period you can find in the record above. We point; the judgment is yours.
- Customer concentrationBusiness
Who the revenue leans on. When one buyer is a large slice of sales, that buyer holds the pricing power, and its troubles become the company's.
“Sales to our largest customer, a U.S. veterinary distributor, represented approximately 16 % of total revenue for 2025, 14 % of total revenue for 2024 and 15 % of total revenue for 2023. 5.”
From the recordRevenue exposed (TTM)$9.5B - Pricing power & competitionRisk Factors
Whether the company sets its price or takes it. Durable pricing power is the surest mark of a moat; price competition is the surest mark there isn't one.
“The animal health industry is highly competitive.”
From the recordOperating margin37.5% (TTM), near a 10-yr high - Concentrated dependenceBusiness
What the whole business leans on, a product, a platform, a partner. Concentration cuts both ways, and the filing is where management has to admit it.
“Derivative Financial Instruments Foreign Exchange Risk A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates.”
From the recordOwner-earnings margin at stake (TTM)23% - Debt terms & refinancingBusiness
The fine print behind the debt. Covenants and near-term maturities decide who is really in control when a year goes badly.
“The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.50:1.”
From the recordBalance sheet (TTM)$7.5B meaningful net debt · interest covered 16.1× - Litigation & contingenciesBusiness
Claims an owner inherits. Most disclosure is boilerplate; this fires only on an actual matter, a named suit, a settlement, a contingency, a number.
“Our non-tax contingencies include, among others, the following: Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.”
A judgment, not a number, weigh it against the filing yourself. - Cyclicality & demandRisk Factors
How the business behaves when the economy turns. A cyclical earns its keep across the whole cycle, not at the peak.
“The overall economic environment In addition to industry-specific factors, we, like other businesses, face challenges related to global economic conditions, an economic downturn and high inflation.”
From the recordWorst year on record28.6% operating margin (FY2016) - Regulation & policyBusiness
Rules that can rewrite the economics, tariffs, antitrust, data, export controls.
“During 2025, 23.9 million shares were repurchased for $3.2 billion, which excludes a $31 million accrual for excise tax on net share repurchases.”
A judgment, not a number, weigh it against the filing yourself.
What changed, FY2025 vs FY2024
read the 10-K →Most of a 10-K is boilerplate carried over verbatim; the signal is in what's new. These lines appear this year and weren't there last, figure updates filtered out, so only the language shift remains.
- “Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the International segment. 2025 vs. 2024 Other business activities net loss was flat in 2025 compared with 2024, reflecting a decrease in R&D costs primarily due to timing of spend related to …”
- “Operational revenue growth was primarily due to the following: price growth of approximately 4%; volume growth from other in-line products of approximately 1%; and volume growth from key franchises of approximately 1%, partially offset by: volume decrease related to the impact of the divestiture of …”
- “The operational changes in connection with the Expected Fiscal Year Alignment to date also included a shift implemented in early 2026 to the timing of annual price increases in certain International Subsidiaries so that the price increase and anticipated customer buying preceding the price increase …”
- “During 2024, we received $ 303 million in sales proceeds, less cash sold of $ 11 million, resulting in $ 292 million net sales proceeds, and recorded a net pre-tax loss of $ 25 million within Other (income)/deductions—net , subject to final post-closing adjustments.”
Classic text analysis over the filing itself, no model wrote a word of this, and every quote is the company's own.
Peers, Pharma
The same industry, side by side on owner economics, compare, don't rank by a single number.● marks best in the group.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| AMGNAmgen Inc. | $36.8B | 67% | 24.7% | 14% | 22% |
| GILDGilead Sciences, Inc. | $29.4B | 79% | 34.0% | 17% | 32% |
| REGNRegeneron Pharmaceuticals, Inc. | $14.3B | 97% | 24.9% | 10% | 28% |
| VRTXVertex Pharmaceuticals Inc / MA | $12.0B | 86% | 34.8% | 26% | 27% |
| BIIBBiogen Inc. | $9.9B | 76% | 28.7% | 11% | 21% |
| ZTSZoetis Inc. | $9.5B | 72% | 37.8% | 26% | 24% |
| IDXXIdexx Laboratories Inc /de | $4.3B | 62% | 31.6% | 51% | 25% |
| MRNAModerna, Inc. | $1.9B | 55% | -158.1% | -37% | -106% |